Displaying 801 - 820 of 1628
Statement of Chairwoman Edith Ramirez and Commissioner Julie Brill In the Matter of i-Health, Inc. and Martek Biosciences Corporation
Supplement Marketers Settle FTC Charges that “BrainStrong Adult” Memory Improvement Claims Are Deceptive
Company Settles FTC Charges that Head Lice Prevention Claims Were Deceptive
FTC Charges Green Coffee Bean Sellers with Deceiving Consumers through Fake News Sites and Bogus Weight Loss Claims
FTC Approves Final Consent Orders Settling Charges that Companies Deceptively Claimed Their Genetically Modified Nutritional Supplements Could Treat Diseases
FTC Staff: Missouri Should Consider Changing Physician Supervision Requirements for Advanced Practice Registered Nurses
FTC Staff Comment Before the Missouri House of Representatives Regarding Missouri House Bills 1481 and 1491
FTC Announces Agenda, Panelists for Upcoming Seminar on Privacy Implications of Consumer Generated and Controlled Health Data
Banning Foreign Pharmacies from Sponsored Search: The Online Consumer Response
FTC Approves Final Order Settling Charges That Community Health Systems, Inc.’s Acquisition of Health Management Associates Inc. was Anticompetitive in Two Local Markets
FTC Puts Conditions on Akorn Enterprises’ Proposed Purchase of Hi-Tech Pharmacal
FTC Approves Final Consent Settling Charges that L’Occitane, Inc. Misled Consumers to Believe that Creams Could Slim Their Bodies
Thermo Fisher Scientific Inc., In the Matter of
Thermo Fisher Scientific Inc. agreed to sell assets to GE Healthcare to settle Federal Trade Commission charges that its proposed $13.6 billion acquisition of Life Technologies Corporation (Life) would likely substantially lessen competition.The FTC complaint alleged that the deal, as it was originally proposed, would have eliminated close competition between Thermo Fisher and Life and substantially increased concentration in the markets for short/small interfering ribonucleic acid (siRNA) reagents, cell culture media, and cell culture sera, enabling the combined firm to raise prices and reduce quality for consumers. The proposed order settling the FTC’s charges requires Thermo Fisher to divest its gene modulation business Dharmacon, which contains the siRNA reagents business, as well as its cell culture media and sera business including the HyClone brand to GE Healthcare, along with all intellectual property and know-how necessary to operate each of the divested businesses.
FTC Chairwoman Releases 2013 Annual Highlights
Displaying 801 - 820 of 1628